Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme that recurs or progresses after receiving chemotherapy and radiation therapy.

15 Apr 2011

Plasma biomarkers can predict risk of metastasis in patients with melanoma

Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

15 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.

7 Apr 2011

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.

7 Apr 2011

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson Pharmaceuticals, Inc. today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application.

1 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

Study finds frequent anaemia in patients with chronic respiratory failure

A study of nearly 600 patients with severe non-inflammatory respiratory disease has found that a significant percentage also suffered from anaemia, according to the April issue of IJCP, the International Journal of Clinical Practice.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Anemia News and Research

Further Reading

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

Plasma biomarkers can predict risk of metastasis in patients with melanoma

Experts to discuss latest findings in IBD research at Rome meeting

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam defends against Tekmira complaint, files answer and counterclaim

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Study finds frequent anaemia in patients with chronic respiratory failure

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News